A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection

NCT01316237 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: GS-6620
DRUG: GS-6620
DRUG: GS-6620
DRUG: GS-6620
DRUG: GS-6620
DRUG: GS-6620
DRUG: GS-6620 tablet, 450 mg BID
DRUG: GS-6620 tablet
DRUG: GS-6620 tablet

Sponsor

Gilead Sciences